HealthDay News — In July to August 2025, about one in 10 US adults reported taking a glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication during the past year, according to research ...
The FDA has approved once-daily oral Infilbray (venglustat) as the first therapy indicated to treat neurological manifestations of type 3 Gaucher disease in adults and pediatric patients weighing at ...
Livsayis (cemdisiran) is the first siRNA therapy and first quarterly subcutaneous treatment for adults with anti-AChR antibody–positive generalized myasthenia gravis.
Intrathecal adrabetadex reduced the risk of death by 55% compared with weighted external controls in patients whose ...
Health care providers and pharmacies should quarantine lot PK25110035 of the 60mg extended-release capsules, which may contain metal fragments capable of causing gastrointestinal soft-tissue ...
Five new treatments across rheumatology, nephrology, cardiology, dermatology, and endocrinology await FDA approval decisions before year-end 2026.
Secukinumab (Cosentyx) 150mg is now FDA approved as the first anti–interleukin-17A biologic for adults with polymyalgia rheumatica who have an inadequate response to corticosteroids or cannot tolerate ...
Supported by phase 3 PREVAIL data, the dual-binding nanobody complement C5 inhibitor provides rapid, sustained functional ...
Neladalkib (Nelkarmi) is now FDA-approved for adults with locally advanced or metastatic ALK-positive NSCLC previously treated with alectinib alone or with 2 or more ALK TKIs plus platinum-based ...
During the 2026 ACAAI Annual Scientific Meeting, Scott Commins, MD, PhD, describes the clinical nuances and presentation of ...
More than a year of nonstop spread and more than 5400 cases this year mean unvaccinated children face a risk the country hasn’t seen in decades ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results